US EditionFDA Approves Generic Form of Rivaroxaban for CAD and PAD
Summary by JAMA Network
1 Articles
1 Articles
All
Left
Center
Right
FDA Approves Generic Form of Rivaroxaban for CAD and PAD
The US Food and Drug Administration (FDA) recently approved the first generic versions of the anticoagulant rivaroxaban, marketed as Xarelto, to reduce the risk of major cardiovascular events in adults with coronary artery disease (CAD) and major thrombotic vascular events in adults with peripheral artery disease (PAD).
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
